Equity Profile

BIIB

Biogen Inc.

Health CareBiotechnology$31.1B

Apr29Wed

Post-Earnings Recap

ReportedQ1-2026Pre-Market6:00 AM EDT

Biogen Beats on EPS, Stock Up 0.0%

Metric	Actual	Expected	Surprise
EPS	$3.57	$2.98	+20.85%
Revenue	N/A	$2.2B	N/A

management commentary, guidance changes, and full analysis available with Pro.

Biogen Beats on EPS, Stock Up 0.0%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$3.57	$2.98	+20.85%
Revenue	N/A	$2.2B	N/A

Management Commentary

Tone: Cautiously Optimistic

Overall, management expressed a cautious optimism about the company's future. They noted strong performance in certain areas but acknowledged ongoing market challenges.

Management highlighted strong performance in key therapeutic areas.

They emphasized ongoing commitment to innovation despite market challenges.

What It Means

Biogen's earnings report showed a significant beat on EPS, which may indicate better-than-expected operational efficiency or cost management. However, the stock reaction remained flat, suggesting that investors may be cautious about the lack of revenue data and forward guidance. The management's cautious tone reflects ongoing challenges in the market, which could impact future performance.

Company Snapshot

Biogen Inc. is a biotechnology company focused on developing therapies for neurological diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating income.

$2.98

Revenue

Revenue figures help investors gauge the overall sales performance and market demand for Biogen's products.

$2.2B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Biogen Inc. is a biotechnology company focused on developing therapies for neurological diseases. With a market cap of $27 billion, it plays a crucial role in the healthcare sector, especially in addressing conditions like Alzheimer's and multiple sclerosis.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+16.70%

Avg Stock Reaction

+1.25%

Last Quarter Recap

In the last quarter, Biogen reported an EPS of $1.99, exceeding expectations by 23.37%. The stock reacted positively, gaining 8.53% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Biogen to report solid earnings this quarter, with a consensus EPS of $2.98 and revenue of $2.2 billion. The company has a strong track record of beating earnings estimates.

Bull Case

If Biogen can continue its trend of beating earnings expectations, it may signal strong demand for its products and effective cost management, potentially driving the stock higher.

Bear Case

On the other hand, if the company fails to meet these expectations, it could raise concerns about its growth prospects and lead to a decline in stock price.

Key Metrics to Watch

EPS

$2.98

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating income.

Revenue

$2.2B

Revenue figures help investors gauge the overall sales performance and market demand for Biogen's products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Biogen's EPS exceed the consensus estimate of $2.98?

A beat on EPS could reinforce investor confidence in the company's ability to manage costs and drive profitability.

What is the outlook for revenue growth this quarter?

Understanding revenue trends will provide insight into market demand for Biogen's products and its competitive position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Biogen's ability to innovate and expand its product offerings, particularly in the Alzheimer's space.

Supporting Evidence

Biogen has a history of beating earnings estimates, with an 88% EPS beat rate over the last eight quarters.

The options market is pricing a larger move than historical averages, indicating potential for a significant reaction.

Recent insider buying could suggest confidence in upcoming results.

Key Risk

If Biogen's new product pipeline shows promising results, it could significantly alter market expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on Biogen's ability to meet or exceed earnings expectations amidst a competitive healthcare landscape.

Bull Confirmed If

An EPS of $3.10 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $2.80 would support the bear case, raising concerns about profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±4.82%

Historical Avg

±3.0%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±4.8% while BIIB has averaged ±3.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

32.4%

Calls (122K)P/C Ratio: 1.02Puts (155K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Biogen beats expectations, history suggests the stock could rise by around 1.24%, confirming strong demand and management effectiveness.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

Should Biogen miss estimates, the stock could see a decline of approximately 0.12%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug approvals or clinical trial results.
2Insights into market demand for existing therapies.
3Management's commentary on cost management strategies.
4Guidance on revenue expectations for the upcoming quarters.
5Details on competitive pressures in the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Apr27

OMABReported

Grupo Aeroportuario del Centro Norte, S.A.B. de C.V.

RecapView

Apr27

PIIReported

Company Snapshot

Biogen Inc. is a biotechnology company focused on developing therapies for neurological diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating income.

$2.98

Revenue

Revenue figures help investors gauge the overall sales performance and market demand for Biogen's products.

$2.2B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+16.70%

Avg Stock Reaction

+1.25%

Last Quarter Recap

In the last quarter, Biogen reported an EPS of $1.99, exceeding expectations by 23.37%. The stock reacted positively, gaining 8.53% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Biogen to report solid earnings this quarter, with a consensus EPS of $2.98 and revenue of $2.2 billion. The company has a strong track record of beating earnings estimates.

Bull Case

If Biogen can continue its trend of beating earnings expectations, it may signal strong demand for its products and effective cost management, potentially driving the stock higher.

Bear Case

On the other hand, if the company fails to meet these expectations, it could raise concerns about its growth prospects and lead to a decline in stock price.

Key Metrics to Watch

EPS

$2.98

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating income.

Revenue

$2.2B

Revenue figures help investors gauge the overall sales performance and market demand for Biogen's products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Biogen's EPS exceed the consensus estimate of $2.98?

A beat on EPS could reinforce investor confidence in the company's ability to manage costs and drive profitability.

What is the outlook for revenue growth this quarter?

Understanding revenue trends will provide insight into market demand for Biogen's products and its competitive position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Biogen's ability to innovate and expand its product offerings, particularly in the Alzheimer's space.

Supporting Evidence

Biogen has a history of beating earnings estimates, with an 88% EPS beat rate over the last eight quarters.

The options market is pricing a larger move than historical averages, indicating potential for a significant reaction.

Recent insider buying could suggest confidence in upcoming results.

Key Risk

If Biogen's new product pipeline shows promising results, it could significantly alter market expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on Biogen's ability to meet or exceed earnings expectations amidst a competitive healthcare landscape.

Bull Confirmed If

An EPS of $3.10 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $2.80 would support the bear case, raising concerns about profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±4.82%

Historical Avg

±3.0%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±4.8% while BIIB has averaged ±3.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

32.4%

Calls (122K)P/C Ratio: 1.02Puts (155K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Biogen beats expectations, history suggests the stock could rise by around 1.24%, confirming strong demand and management effectiveness.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

Should Biogen miss estimates, the stock could see a decline of approximately 0.12%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug approvals or clinical trial results.
2Insights into market demand for existing therapies.
3Management's commentary on cost management strategies.
4Guidance on revenue expectations for the upcoming quarters.
5Details on competitive pressures in the biotechnology sector.